HBCV-HCC patients exhibited lower tumor grade (grade 3–4: 29% vs. 42%, P = 0.0345*) and lower AFP level (≥ 100 ng/mL: 27% vs. 43%, P = 0.0061**) than mono-infected HCC patients. This evidence concerns the gene AFP and hepatocellular carcinoma.